Concert Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 0.008 million compared to USD 0.543 million a year ago. Net loss was USD 28.9 million compared to USD 26.68 million a year ago. Basic loss per share from continuing operations was USD 0.58 compared to USD 0.78 a year ago. Diluted loss per share from continuing operations was USD 0.58 compared to USD 0.78 a year ago.
For the nine months, revenue was USD 0.029 million compared to USD 32.57 million a year ago. Net loss was USD 90.18 million compared to USD 43.92 million a year ago. Basic loss per share from continuing operations was USD 2.13 compared to USD 1.29 a year ago. Diluted loss per share from continuing operations was USD 2.13 compared to USD 1.29 a year ago.